The course of melanoma-associated vitiligo: report of a case
- 1 August 2006
- journal article
- case report
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 16 (4) , 371-373
- https://doi.org/10.1097/01.cmr.0000222590.68234.1d
Abstract
The appearance of vitiligo-like lesions in patients with malignant melanoma is a well-known yet uncommon phenomenon. This finding is especially reported in patients undergoing immunotherapy with or without chemotherapy for malignant melanoma and is generally believed to be associated with a better prognosis. We report a case of preexisting vitiligo in a 48-year-old man, aggravated after chemo-immunotherapy of pulmonary metastatic melanoma with interferon-alpha, vinblastine and dacarbazine. Skin lesions remained stable after discontinuation of the treatment, and repigmentation heralded the recurrence of metastatic disease. These findings were in favor of vitiligo being a marker of the immunity against melanoma cells and its favorable impact on the prognosis of melanoma patients.Keywords
This publication has 24 references indexed in Scilit:
- Prognostic Significance of Autoimmunity during Treatment of Melanoma with InterferonNew England Journal of Medicine, 2006
- Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma PatientsJournal of Clinical Oncology, 2005
- A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant MelanomaDermatology, 2004
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProceedings of the National Academy of Sciences, 2003
- Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2001
- Melanoma and vitiligo: immunology's Grecian urnCancer Immunology, Immunotherapy, 1996
- Therapy of disseminated malignant melanoma with recombinant α 2b-interferon and piroxicam: Clinical results with a report of an unusual response-associated feature (Vitiligo) and unusual toxicity (diffuse pulmonary interstitial fibrosis)Medical and Pediatric Oncology, 1994
- Sequential chemoimmunotherapy in the treatment of metastatic melanoma.Journal of Clinical Oncology, 1992
- Vitiligo and Cutaneous MelanomaDermatology, 1991
- Hypopigmentation, Vitiligo, and MelanomaArchives of Dermatology, 1987